An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing a ...

While it has merit as a policy measure, it's the latest in a brutal series of administration actions that have hurt ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000 ®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Keratoconus has long been associated with atopic conditions like asthma, eczema and allergic conjunctivitis, and this ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to ...

The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints59% of patients ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...